Evidence map›Paper›PMID 40483349›Full record

ArticleNPJ Regenerative medicine2025

Prevention of nerve growth and evoked pain with a nerve cap graft device.

Sydney Borcherding, Matthew D Wood, Sai L Pinni, Lauren Schellhardt, Anne E Faust, Marissa N Behun, Clint Skillen, Pooja Chawla, Mangesh Kulkarni, Elena A Demeter and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ Regenerative medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sydney BorcherdingRenerva, Inc., Pittsburgh, PA, USA.
Matthew D WoodDivision of Plastic and Reconstructive Surgery, Department of Surgery, Washington University in St. Louis School of Medicine, St. Louis, MO, USA.
Sai L PinniDivision of Plastic and Reconstructive Surgery, Department of Surgery, Washington University in St. Louis School of Medicine, St. Louis, MO, USA.
Lauren SchellhardtDivision of Plastic and Reconstructive Surgery, Department of Surgery, Washington University in St. Louis School of Medicine, St. Louis, MO, USA.
Anne E FaustRenerva, Inc., Pittsburgh, PA, USA.
Marissa N BehunRenerva, Inc., Pittsburgh, PA, USA.
Clint SkillenMcGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Pooja ChawlaRenerva, Inc., Pittsburgh, PA, USA.
Mangesh KulkarniMcGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Elena A DemeterDepartment of Population Medicine and Diagnostic Sciences, Section of Anatomic Pathology, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA.
Andrew D MillerDepartment of Population Medicine and Diagnostic Sciences, Section of Anatomic Pathology, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA.
Mark A MahanDepartment of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, UT, USA.
Bryan N BrownRenerva, Inc., Pittsburgh, PA, USA. brownb@upmc.edu.
Lorenzo SolettiRenerva, Inc., Pittsburgh, PA, USA. lsoletti@renerva.com.

Funding

National Science Foundation 2151582
6 · The paper itself

Abstract

Neuroma following nerve injury and/or amputation is a debilitating condition with significant impacts on quality of life. Several approaches exist to prevent or treat neuroma and/or reduce associated pain; however, these approaches are not consistently effective, facile, or widely accessible. The present study characterizes a xenogeneic nerve cap graft device (NCGD) composed of decellularized porcine nerve. The NCGD was assessed for its ability to inhibit nerve growth, neuroma formation, and pain in rodent models of sciatic neurectomy and tibial neuroma transposition. The NCGD provided a neuroinhibitory substrate that abated and interrupted nerve growth within 5 mm of the nerve stump and was progressively remodeled into healthy host-derived tissue. The NCGD also resulted in a 3.5-fold reduction in evoked pain and a decrease in pain-associated markers at the dorsal root ganglia. These results suggest that the NCGD may provide a simple and widely accessible alternative for prophylactic treatment of symptomatic neuroma.

Identifiers

PMID40483349
PMCPMC12145427

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.